My primary fields of interest are the discovery and development (research-to-GMP) of immunoglobulins of high potential therapeutic interest using a variety of formats, novel molecular strategies for targeting solid tumors and the basis of TCR/pMHC recognition and how best to assess/predict potential cross-reactivity of pMHC targeting agents.